Xenetic Biosciences, Inc. (XBIO)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, Xenetic Biosciences, Inc. reported revenue of $2.98M, up 19.0% from the prior year. The company ran a net loss, with a net margin of -90.1%. It held $8.36M in total assets against $968.0K in total liabilities.
Key ratios (FY2025)
-95.2%
Operating margin
-90.1%
Net margin
-36.2%
Return on equity
+19.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.98M | $2.50M | $2.54M | $1.71M | $1.16M | $436.9K | $17.1K | $0 | $7.58M | $3.00M |
| Operating Income | -$2.83M | -$4.20M | -$4.52M | -$6.72M | -$5.75M | -$13.94M | -$12.89M | -$7.28M | -$3.57M | -$47.43M |
| Net Income | -$2.68M | -$3.96M | -$4.13M | -$6.55M | -$5.65M | -$10.89M | -$12.78M | -$7.30M | -$3.60M | -$54.21M |
| EPS (Diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | — | — | — | — | — |
| Total Assets | $8.36M | $6.90M | $10.61M | $14.72M | $19.82M | $13.18M | $21.55M | $14.43M | $19.16M | $20.97M |
| Total Liabilities | $968.0K | $894.3K | $809.6K | $1.07M | $1.42M | $964.0K | $4.33M | $4.52M | $4.86M | $4.80M |
| Shareholders' Equity | $7.40M | $6.01M | $9.80M | $13.65M | $18.39M | $12.22M | $17.21M | $9.91M | $14.30M | $16.17M |
| Operating Cash Flow | -$2.29M | -$2.82M | -$4.11M | -$4.65M | -$4.74M | -$4.27M | -$6.40M | -$6.46M | $1.49M | -$8.79M |
| Capital Expenditures | — | — | — | — | — | — | — | $0 | $9.3K | $16.8K |
| Shares Outstanding | 2.29M | 1.54M | 1.54M | 1.52M | 13.44M | 8.75M | 6.07M | 9.40M | 8.72M | 4.59M |